aTyr Pharma to Present Data Identifying Fibrosis Target for tRNA Synthetase Candidate ATYR0101 at Keystone Symposia on Fibrosis Pathogenesis and Resolution
21 mars 2023 08h00 HE
|
aTyr Pharma, Inc.
Findings confirm LTBP1, a key regulator of TGF-β, as binding partner for tRNA synthetase DARS fragment ATYR0101 Data indicates ATYR0101 may have therapeutic potential for fibrotic pathologies...
aTyr Pharma Announces Fourth Quarter and Full Year 2022 Results and Provides Corporate Update
09 mars 2023 16h00 HE
|
aTyr Pharma, Inc.
Phase 3 EFZO-FIT™ study of efzofitimod in patients with pulmonary sarcoidosis enrolling in the U.S., Europe and Japan. Phase 2 proof-of-concept study of efzofitimod in patients with SSc-ILD expected...
aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
18 nov. 2022 16h00 HE
|
aTyr Pharma, Inc.
SAN DIEGO, Nov. 18, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary...
aTyr Pharma Receives FDA Fast Track Designation for Efzofitimod (ATYR1923) for Treatment of Pulmonary Sarcoidosis
11 août 2022 08h03 HE
|
aTyr Pharma, Inc.
SAN DIEGO, Aug. 11, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE) (aTyr or “the Company”), a clinical stage biotherapeutics company engaged in the discovery and development of...
aTyr Pharma to Present at BIO CEO & Investor Conference
07 févr. 2022 08h00 HE
|
aTyr Pharma, Inc.
SAN DIEGO, Feb. 07, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological...
aTyr Pharma Announces FDA Orphan Drug Designation for ATYR1923 for Treatment of Sarcoidosis
06 janv. 2022 08h00 HE
|
aTyr Pharma, Inc.
SAN DIEGO, Jan. 06, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotherapeutics company engaged in the discovery and development of innovative medicines based on...
aTyr Pharma to Present at H.C. Wainwright Virtual BioConnect Conference
04 janv. 2022 08h03 HE
|
aTyr Pharma, Inc.
SAN DIEGO, Jan. 04, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological...
aTyr Pharma Appoints Danielle Campbell as Vice President of Human Resources
24 déc. 2021 08h02 HE
|
aTyr Pharma, Inc.
SAN DIEGO, Dec. 24, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological...
aTyr Pharma to Present at Antibody Engineering & Therapeutics Conference
10 déc. 2021 08h00 HE
|
aTyr Pharma, Inc.
SAN DIEGO, Dec. 10, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological...
aTyr Pharma and FUJIFILM Diosynth Biotechnologies Announce Manufacturing Agreement for aTyr’s Lead Therapeutic Candidate ATYR1923
30 nov. 2021 08h00 HE
|
aTyr Pharma, Inc.
SAN DIEGO, Nov. 30, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological...